ArticleMammalian genome : official journal of the International Mammalian Genome Society2026
Knockdown of SOX4 attenuates sepsis myocardial injury by inhibiting the EZH2/H3K27me3/SOCS3 axis.
Article in Mammalian genome : official journal of the International Mammalian Genome Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Inhibition of SOX4 has been reported to ameliorate myocardial ischemic injury, yet its role in sepsis myocardial injury remains unknown. To explore the protective effects and mechanisms of SOX4 inhibition in septic myocardial injury. AC16 cardiomyocytes were exposed to LPS to mimic sepsis-induced myocardial injury. Cell viability was measured by CCK-8 assay, apoptosis by flow cytometry and TUNEL staining, and apoptosis-related proteins by western blot. The connection between SOX4 and EZH2 was validated using co-immunoprecipitation (co-IP) assay and immunofluorescence. Additionally, chromatin immunoprecipitation (ChIP) was employed to detect the enrichment of H3K27me3 in SOCS3 promoter region. The results showed that SOX4 and EZH2 were significantly elevated in septic patients, and their expression levels were positively correlated. In LPS-treated AC16 cardiomyocytes, the expressions of SOX4 and EZH2 increased, while the expression of SOCS3 decreased. Knockdown of SOX4 enhanced AC16 cell viability and inhibited LPS-induced apoptosis. SOX4 and EZH2 colocalized within AC16 cells, and co-IP assays confirmed their interaction. Elevated EZH2 expression reduced the protective impact of SOX4 knockdown in AC16 cells. Silencing EZH2 reduced the enrichment of H3K27me3 in SOCS3 promoter region and thereby promoting SOCS3 expression. Overexpression of SOCS3 promoted AC16 cell survival and partially reversed the damaging effect of EZH2 overexpression on cell survival. Animal experiments confirmed that knockdown of SOX4 attenuated myocardial injury in CLP sepsis mouse model. Knockdown of SOX4 reduces the H3K27me3 methylation level of the SOCS3 promoter by inhibiting EZH2 expression, thereby promoting SOCS3 expression and attenuating myocardial injury.
Indexed as
Identifiers
41803420What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.